The FDA has approved the first option for the treatment of adult and pediatric patients aged 12 years or older with COVID-19 who require hospitalization.
Nonsteroidal anti-inflammatory drugs put the fetus at risk for rare but serious kidney complications.
The US Food and Drug Administration has approved the use of inmazeb, a combination of monoclonal antibodies, for use as the first treatment for Ebola virus infection.
The FDA has approved a new drug combination for the treatment of adults with malignant pleural mesothelioma.
A Janus kinase inhibitor was approved for the treatment of active polyarticular course juvenile idiopathic arthritis among patients aged 2 years or older.
The US Food and Drug Administration has approved the first automated diabetes management system for use in patients aged 2 to 6 years.
A drug that was first approved in 2009 for the treatment of chronic lymphocytic leukemia has now been approved by the FDA to treat relapsing forms of multiple sclerosis.
The US Food and Drug Administration has approved a new treatment for neuromyelitis optica spectrum disorder among adults with the AQP4 antibody.
The US Food and Drug Administration have approved a new option for the management of severe acute pain in adults for whom intravenous opioid use is required.
The US Food and Drug Administration has approved an oral drug for the treatment of spinal muscular atrophy among patients aged 2 years or older.